SELECTIVE HDAC6 INHIBITORS Russian patent published in 2022 - IPC C07D249/12 C07D417/06 C07D417/04 C07D271/10 C07D405/04 C07D401/04 C07D471/04 C07D403/04 C07D405/14 C07D495/04 C07D409/04 C07D405/06 A61K31/4196 A61K31/4245 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound by the formula (I) and (II), pharmaceutically acceptable salts and stereoisomers thereof, wherein A=N, O, S in the formula (I), A=N in the formula (II); B=C, N; C=N, O in the formula (I) when C=N in the formula (II); X=CH₂, S, NH; n=0, 1; when n=1, a carbon atom can be substituted with R¹² and R¹³, independently selected from the group including H, –Me, –phenyl, or together R¹² and R¹³ can form a cyclopropane, cyclobutane, cyclopentane, or cyclohexane; when n=1, R⁶ is not absent; R⁴=R⁵=H, F; R¹ is absent or selected from the group including –H, –NH₂, –C₁–C₄ alkyl, phenyl, phenyl substituted with one or several halogens, methylfuran, methylphenyl, thiophene, and 2–(morpholine–4–yl)ethyl; R² is absent or is selected from phenyl; R³ is absent or selected from o–methoxyphenyl, p–trifluoromethylphenyl, benzyl, or pyridyl; R⁶, R⁷ and R⁸ are defined in the claim of the invention, R⁹=R¹⁰ = –Me, –Et; R¹¹ is selected from the group containing –H, –Cl and –CH₃, provided that when pentachlorocyclohexane core constitutes 1,3,4-oxadiazol, R⁶ is not naphthyl in compounds by the formula (I). The invention also relates to a pharmaceutical composition for treating HDAC6-mediated diseases based on the described compounds.

(I)

(II)

EFFECT: production of new compounds and a pharmaceutical composition based thereon, exhibiting high selective inhibitory activity against the histone deacetylase 6 enzyme (HDAC6), applicable in medicine for treating multiple myeloma, breast cancer, and colon cancer.

8 cl, 5 dwg, 15 tbl, 27 ex